膀胱肿瘤是泌尿外科常见肿瘤疾病之一,近年来其发生率有逐年增加趋势,确诊后应首选手术治疗。经尿道行膀胱肿瘤电切或膀胱部分切除术后,约有50%～70%患者肿瘤复发[1],故一般术后采用膀胱内化疗药物灌注治疗以期杀灭潜在的残留癌细胞,以防复发。随着新型抗肿瘤药物的不断出现,使 Bladder cancer is one of the common tumor diseases in urology. In recent years, its incidence has increased year by year. After the diagnosis, bladder cancer should be the first choice for surgical treatment. Transurethral resection of the bladder tumor or partial resection of the bladder, about 50% to 70% of patients with tumor recurrence [1], so the general treatment of intra-bladder chemotherapy drug infusion in order to kill potential residual cancer cells in case relapse. With the continuous emergence of new anti-cancer drugs